The National Research Foundation was established as an independant government agency, through the National Research Foundation Act [Act No.23 of 1998].
The NRF receives its mandate from the National Research Foundation Act (Act No 23 of 1998, as amended). According to Section 3 of the Act, the object of the NRF is to contribute to national development by:
Chief Executive Officer (CEO)
Group Executive: Finance and Business Systems and (CFO)
Acting DCEO: NRIP
Group Executive: Corporate Services
Group Executve: Digital Transformation Acting DCEO: RIISA
Deputy CEO: Research and Innovation Support and Advancement (RISA)
Call for Proposals: New Earth Observation Frontiers Enterprise Innovation Support Fund
CALL FOR APPLICATIONS FOR EVALUATION AND RATING – 2024
Call for Applications: Globalink Research Award Thematic Call
DSI-NRF Postgraduate Student Funding for the 2024 Academic Year
Invitation for Nominations for Professional Development Programme (PDP) Postdoctoral Fellowships for 2023
2023 iThemba Labs Physics Summer School Call for Applications
Bi-annual Progress Reports: Postgraduate Scholarships 2022 – Mid-Year Reports
1ANNOUNCEMENT OF SUCCESSFUL APPLICATIONS FOR THE DSI-NRF FIRST-TIME GRANT HOLDER-LINKED MASTERS SCHOLARSHIPS FOR FUNDING IN 2024 ACADEMIC YEAR
ANNOUNCEMENT OF SUCCESSFUL APPLICATIONS FOR THE DSI-NRF FIRST-TIME GRANT HOLDER-LINKED DOCTORAL SCHOLARSHIPS FOR FUNDING IN 2024 ACADEMIC YEAR
Call for applications: Summer schools 2024 in Germany for DAAD In-Country/In-Region scholarship holders
Open Calls for Scholarship Applications: Hungary, China, Russia, Mauritius, Sweden and Switzerland
Africa’s leading research facility for accelerator based science. Probing fundamental structure and the origins of matter; Advancing the understanding of condensed matter; Impacting the Societal need through provision for the health and environmental sector
The iThemba Laboratory for Accelerator Based Sciences is the continents' biggest facility for particle and nuclear research.
The SAAO is a national facility of the NRF and the national centre for optical and infrared astronomy in South Africa.
SAEON is a national platform for detecting, translating and predicting environmental change.
SAIAB provides unique skills and infrastructure support in marine, estuarine and freshwater ecosystems research, molecular research, collections and bioinformatics.
SARAO is a national facility of the NRF and incorporates radio astronomy instruments and programmes such as MeerKAT and KAT-7 telescopes in the Karoo, (HartRAO) in Gauteng...
South Africa’s innovation revolution must assist in solving our society’s deep and pressing socio-economic challenges. Global competitiveness, shrinking resource availability, and the requirements of a skilled labour force mean that, increasingly, an awareness and understanding of why science and research are critical to our lives is essential for developing an innovation culture.
Within the next five years, the aim is to begin to more fully embed engagement in and with science in the core NRF missions of supporting and promoting new knowledge and growing new knowledge workers. This is led by the formulation of an acceptable NRF position on engaged research which will guide the NRF approach…
NRF | SAASTA is the NRF business division tasked with leading and coordinating the science engagement programme across the NRF and beyond. The NRF is equally committed to ensuring that the science engagement leadership and national coordination role…
The NRF provides leading-edge research infrastructure platforms that ensure that the national research enterprise has the requisite infrastructure to undertake globally competitive discovery science, train the next generation of researchers, support engagement with science by and with the public and promote innovation that positively impacts society, the environment, the economy.
The annual NRF Awards recognize and celebrate South African research excellence. The awards presented to researchers are in two categories, the ratings linked awards and special recognition awards.
The National Research Foundation (NRF) conducts its procurement of goods, services, and works in accordance with its Supply Chain Management Policy in a manner that is fair, equitable, transparent, competitive, and cost-effective
The National Research Foundation (NRF) is guided by its Supply Chain Management Policy in its procurement of goods and services. The Policy sets out the prescripts issued by National Treasury with the exact note referenced in the footnotes. The Supply Chain Management policy adheres to the National Treasury’s prescribed supply chain system framework.
The NRF’s Supply Chain Management Policy and the conduct of supply chain management at the NRF seeks to give effect to section 217 of the South African Constitution which requires that all procurement of goods and services must be done in a manner that is fair, equitable, transparent, competitive and cost-effective.
The National Research Foundation bid awards and contracts. Below is the latest award.
The National Research Foundation (NRF) of South Africa joins with people across the globe in commemorating World Aids Day 2020. This year, at a time when the world is challenged by the global Covid-19 pandemic, HIV/AIDS remains a major global public health issue. We asked researchers at the DSI-NRF Centre of Excellence in HIV Prevention, and the DSI-NRF Research Chair in HIV Vaccine Translational Research to update us on the status of HIV/AIDS research and the progress that has been made in finding a cure.
The Road to an Effective HIV Vaccine for Prevention
By Professor Caroline T. Tiemessen, DSI-NRF Research Chair of HIV Vaccine Translational Research, University of the Witwatersrand
What we know so far
2020 marks a year where the HIV vaccine field has been delivered another blow – the Phase IIb/III trial called HVTN 702 or Uhambo, which started in 2016, showed no reduced risk of contracting HIV and vaccinations were stopped in February. This large-scale efficacy trial enrolled 5 407 South African men and women. While there was every hope that this HVTN 702 regimen, by design, would have improved on the modest efficacy of 31% seen in the 2009 RV144 vaccine trial conducted in Thailand, there is much we can learn from its failure that will inform future vaccine efforts. The answer lies in one or more of the differences. The HVTN 702 vaccine regimen was adapted for clade C infection (the most common clade in Southern Africa); a different adjuvant was included to enhance responses; and booster vaccinations added to prolong these responses. Another difference lies in the populations vaccinated and warrants a careful evaluation of the contribution of host genetics and environment to these outcomes.
Ongoing large-scale efficacy HIV vaccine trials
Two other large-scale vaccine trials have been underway, using “mosaic-based” vaccines designed to more broadly target different HIV clades across the world. The Phase IIb trial HPX2008/HVTN 705 or Imbokodo, has enrolled 2 600 women in five sub-Saharan African countries (South Africa, Zimbabwe, Mozambique, Malawi and Zambia), while the Phase III trial HVTN 706/HPX3002, or Mosaico, is enrolling 3 800 men who have sex with men (MSM) and transgender people in Argentina, Brazil, Italy, Mexico, Peru, Poland, Spain, and the United States.
Two Phase IIb trials are testing the concept of passive immunisation (direct infusion of a neutralising antibody VRCO1) for protection against acquiring HIV infection. These antibody-mediated prevention (AMP) trials have been conducted in 1 900 sub-Saharan African women (HVTN 703/HPTN 081), and in 2 700 men and transgender persons who have sex with men (HVTN 704/HPTN 085) in Brazil, Peru, Switzerland, and the United States. Results from these AMP trials are imminent.
The COVID-19 pandemic has resulted in the delay of the start of a planned Phase IIb trial of a novel combination approach of oral PreP and experimental vaccines. This trial, called PrEPVacc, will enrol 1 668 men and women from Uganda, South Africa, Tanzania and Mozambique.
There are many other promising vaccine approaches in earlier stages of development.
The ongoing quest to find an HIV cure
Sadly, 2020 marks the loss of a fierce advocate for HIV cure research – Timothy Ray Brown. Also known as the “Berlin patient,” he was the first patient recognised as cured of HIV. He received two bone marrow transplants, a year apart, from the same donor with a mutation in CCR5, which prevents HIV from entering cells. Following in his footsteps as the second case of cure through stem cell transplantation also from a CCR5-deficient donor, the “London patient” was identified in 2019. Recent findings in a study of elite controllers (people who naturally suppress their virus to undetectable levels in the absence of antiretroviral drugs) identified a single patient who may have eliminated all cells that contain HIV that can replicate (known as replication-competent virus). The thinking is that vigorous immune responses may have eliminated such cells over time, leaving only cells containing remnants of HIV DNA that cannot produce the virus. Post-treatment controllers (who, usually following a period of early antiretroviral treatment, suppress virus to undetectable levels) are another group of interest. A recent report of the “Brazilian patient” who was not treated early but received an intensified regimen of antiretroviral drugs, achieved undetectable virus off drugs for 15 months. Our local example of a South African post-treatment controller child who received early treatment for a year which was then stopped continues to maintain undetectable virus with standard tests – now 12 years off antiretroviral treatment. To date, we have found no evidence of replication-competent virus with more sophisticated tests, however these are ongoing.
Examples of remarkable cases that have achieved undetectable HIV with or without some intervention tell us that it is possible to achieve an HIV cure. The scientific challenge remains how we use the knowledge we gain from these examples and turn them into effective strategies for cure. Among the approaches being pursued are therapeutic vaccines, broadly neutralising antibodies, toll-like receptor agonists and gene therapies.
Announcement of Supplementary Successful Extension Applications for Centres of Excellence (CoE) Masters and Doctoral Scholarships for Studies in 2021
The Role of Immunity and immune memory against viruses
Hit enter to search or ESC to close